Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors

Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access

(2016) Tim K. Mackey et al.   BMC Medicine

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

(2015) Hinke F. van Thuijl et al.   ACTA NEUROPATHOLOGICA

Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer

(2015) C. Rothermundt et al.   ANNALS OF ONCOLOGY

Radiotherapy Complements Immune Checkpoint Blockade

(2015) Shin Foong Ngiow et al.   CANCER CELL

High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan

(2015) Nisreen Amayiri et al.   INTERNATIONAL JOURNAL OF CANCER

Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results

(2015) Felix Bokstein et al.   JOURNAL OF NEURO-ONCOLOGY

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment

(2015) J. V. Cohen et al.   Cancer Immunology Research

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck

(2014) Dan P. Zandberg et al.   ORAL ONCOLOGY

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

(2014) Scott Tykodi   OncoTargets and Therapy

Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children

(2013) Tene A. Cage et al.   CHILDS NERVOUS SYSTEM

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Principles of Conservative Prescribing

(2011) Gordon D. Schiff   ARCHIVES OF INTERNAL MEDICINE

Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas

(2010) Shannon E. Fogh et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY